MA51288A - Analogues d'incrétine et leurs utilisations - Google Patents
Analogues d'incrétine et leurs utilisationsInfo
- Publication number
- MA51288A MA51288A MA051288A MA51288A MA51288A MA 51288 A MA51288 A MA 51288A MA 051288 A MA051288 A MA 051288A MA 51288 A MA51288 A MA 51288A MA 51288 A MA51288 A MA 51288A
- Authority
- MA
- Morocco
- Prior art keywords
- incretin
- analogues
- incretin analogues
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Details Of Garments (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762608613P | 2017-12-21 | 2017-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51288A true MA51288A (fr) | 2021-03-31 |
Family
ID=65003519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051288A MA51288A (fr) | 2017-12-21 | 2018-12-14 | Analogues d'incrétine et leurs utilisations |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11542313B2 (fr) |
| EP (1) | EP3727426A1 (fr) |
| JP (2) | JP6961838B2 (fr) |
| KR (2) | KR102444783B1 (fr) |
| CN (1) | CN111491658B (fr) |
| AR (1) | AR113486A1 (fr) |
| AU (1) | AU2018388962B2 (fr) |
| BR (1) | BR112020010244A2 (fr) |
| CA (1) | CA3084005C (fr) |
| CL (1) | CL2020001635A1 (fr) |
| CO (1) | CO2020006255A2 (fr) |
| CR (1) | CR20200255A (fr) |
| DO (1) | DOP2020000123A (fr) |
| EA (1) | EA202091290A1 (fr) |
| EC (1) | ECSP20032650A (fr) |
| IL (1) | IL275468A (fr) |
| JO (1) | JOP20200137A1 (fr) |
| MA (1) | MA51288A (fr) |
| MX (1) | MX2020006548A (fr) |
| PE (1) | PE20210162A1 (fr) |
| PH (1) | PH12020551025A1 (fr) |
| SG (1) | SG11202005606VA (fr) |
| TW (3) | TWI809515B (fr) |
| WO (1) | WO2019125938A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR113486A1 (es) * | 2017-12-21 | 2020-05-06 | Lilly Co Eli | Análogos de incretina y sus usos |
| AU2020334993B2 (en) | 2019-08-19 | 2023-07-13 | Eli Lilly And Company | Methods of making incretin analogs |
| TWI795698B (zh) * | 2019-12-18 | 2023-03-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| WO2021193984A2 (fr) * | 2020-03-25 | 2021-09-30 | Takeda Pharmaceutical Company Limited | Dosage d'une fois par jour de composés peptidiques de l'agoniste du récepteur du gip et leurs utilisations |
| JP2023550594A (ja) | 2020-10-30 | 2023-12-04 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１、ｇｉｐ、およびグルカゴン受容体三重作動薬 |
| CN114685642B (zh) * | 2020-12-29 | 2024-03-29 | 浙江和泽医药科技股份有限公司 | 一种肠促胰岛素类似物药学上可接受盐及制备方法和用途 |
| KR20230125093A (ko) | 2021-01-20 | 2023-08-28 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| TWI837615B (zh) | 2021-03-23 | 2024-04-01 | 美商美國禮來大藥廠 | 含腸促胰島素(incretin)類似物之組合物及其用途 |
| AU2022280225A1 (en) | 2021-05-26 | 2024-01-04 | The United Bio-Technology (Hengqin) Co., Ltd. | Multi-agonist and use thereof |
| WO2022268029A1 (fr) * | 2021-06-21 | 2022-12-29 | 广东东阳光药业有限公司 | Agoniste triple pour récepteurs glp-1, gcg et gip |
| JP2024524180A (ja) | 2021-06-23 | 2024-07-05 | イーライ リリー アンド カンパニー | インクレチン類似体の使用方法及びインクレチン類似体を含む組成物 |
| AU2022392980A1 (en) * | 2021-11-19 | 2024-07-04 | Medshine Discovery Inc. | Stapled peptide and use thereof |
| TWI828434B (zh) * | 2021-11-19 | 2024-01-01 | 大陸商南京明德新藥研發有限公司 | 釘合肽及其應用 |
| CN116162147B (zh) * | 2021-11-24 | 2023-10-03 | 成都奥达生物科技有限公司 | 一种长效胰岛素类似物 |
| CN114957387B (zh) * | 2022-05-18 | 2023-06-20 | 华南理工大学 | 一种具有降血糖作用的巴旦木多肽及其制备方法与应用 |
| WO2024050289A1 (fr) | 2022-08-29 | 2024-03-07 | Eli Lilly And Company | Compositions pour administration orale |
| CN117417411A (zh) * | 2022-09-28 | 2024-01-19 | 广东东阳光药业股份有限公司 | Glp-1/gcg/gip三受体激动剂及其用途 |
| WO2024077149A2 (fr) | 2022-10-05 | 2024-04-11 | Eli Lilly And Company | Peptides pour la synthèse d'incrétine |
| WO2024141760A1 (fr) | 2022-12-30 | 2024-07-04 | Algipharma As | Compositions et procédés pour augmenter la biodisponibilité systémique d'un agent thérapeutique polypeptidique subissant une administration orale |
| CN117024528B (zh) * | 2023-07-07 | 2024-03-22 | 杭州信海医药科技有限公司 | 一种Retatrutide的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010011439A2 (fr) * | 2008-06-17 | 2010-01-28 | Indiana University Research And Technology Corporation | Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l’obésité |
| MX2011010151A (es) | 2009-03-27 | 2011-12-14 | Glaxo Group Ltd | Fusiones y conjugados de farmaco. |
| EA026384B1 (ru) * | 2010-01-20 | 2017-04-28 | Зилэнд Фарма А/С | Лечение заболеваний сердца |
| AR080592A1 (es) * | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| EP2707713A2 (fr) * | 2011-05-10 | 2014-03-19 | Zealand Pharma A/S | Composés sélectifs pour une signalisation d'agonistes doubles de glu-glp1 |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| JP6682432B2 (ja) * | 2013-11-06 | 2020-04-15 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
| EP3066117B1 (fr) * | 2013-11-06 | 2019-01-02 | Zealand Pharma A/S | Composés agonistes triples glucagon-glp-1-gip |
| JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| WO2016198624A1 (fr) | 2015-06-12 | 2016-12-15 | Sanofi | Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip |
| TWI783244B (zh) * | 2015-06-22 | 2022-11-11 | 美商美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
| TWI622596B (zh) * | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| TN2018000231A1 (en) | 2015-12-31 | 2019-10-04 | Hanmi Pharm Ind Co Ltd | Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist |
| EP3217027A1 (fr) | 2016-03-08 | 2017-09-13 | HILTI Aktiengesellschaft | Élement de revetement large destine a entourer une tige d'ancrage |
| AR113486A1 (es) * | 2017-12-21 | 2020-05-06 | Lilly Co Eli | Análogos de incretina y sus usos |
| TWI767095B (zh) * | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
-
2018
- 2018-12-05 AR ARP180103560A patent/AR113486A1/es unknown
- 2018-12-05 TW TW110136047A patent/TWI809515B/zh active
- 2018-12-05 TW TW112124080A patent/TW202415675A/zh unknown
- 2018-12-05 TW TW107143624A patent/TWI744579B/zh active
- 2018-12-14 WO PCT/US2018/065663 patent/WO2019125938A1/fr unknown
- 2018-12-14 US US16/768,960 patent/US11542313B2/en active Active
- 2018-12-14 PE PE2020000802A patent/PE20210162A1/es unknown
- 2018-12-14 CN CN201880081212.3A patent/CN111491658B/zh active Active
- 2018-12-14 JO JOP/2020/0137A patent/JOP20200137A1/ar unknown
- 2018-12-14 AU AU2018388962A patent/AU2018388962B2/en active Active
- 2018-12-14 SG SG11202005606VA patent/SG11202005606VA/en unknown
- 2018-12-14 MA MA051288A patent/MA51288A/fr unknown
- 2018-12-14 EP EP18830618.7A patent/EP3727426A1/fr active Pending
- 2018-12-14 KR KR1020207017387A patent/KR102444783B1/ko active IP Right Grant
- 2018-12-14 MX MX2020006548A patent/MX2020006548A/es unknown
- 2018-12-14 CA CA3084005A patent/CA3084005C/fr active Active
- 2018-12-14 CR CR20200255A patent/CR20200255A/es unknown
- 2018-12-14 JP JP2020551786A patent/JP6961838B2/ja active Active
- 2018-12-14 EA EA202091290A patent/EA202091290A1/ru unknown
- 2018-12-14 KR KR1020227031761A patent/KR102622642B1/ko active IP Right Grant
- 2018-12-14 BR BR112020010244-0A patent/BR112020010244A2/pt unknown
-
2020
- 2020-05-22 CO CONC2020/0006255A patent/CO2020006255A2/es unknown
- 2020-06-17 IL IL275468A patent/IL275468A/en unknown
- 2020-06-17 PH PH12020551025A patent/PH12020551025A1/en unknown
- 2020-06-17 CL CL2020001635A patent/CL2020001635A1/es unknown
- 2020-06-17 DO DO2020000123A patent/DOP2020000123A/es unknown
- 2020-06-19 EC ECSENADI202032650A patent/ECSP20032650A/es unknown
-
2021
- 2021-10-13 JP JP2021168050A patent/JP2022033724A/ja active Pending
-
2022
- 2022-11-21 US US18/057,398 patent/US20230203121A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51288A (fr) | Analogues d'incrétine et leurs utilisations | |
| MA51287A (fr) | Analogues d'incrétine et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
| MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
| MA50502A (fr) | Adénovirus et utilisations associées | |
| MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
| MA41460A (fr) | Agents de liaison à la tnfrsf et leurs utilisations | |
| MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
| MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| MA46471A (fr) | Protéines actriib à variant et leurs utilisations | |
| MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
| MA53145A (fr) | Agents de liaison cd123 et leurs utilisations | |
| MA50397A (fr) | Anticorps anti-tau et leurs utilisations | |
| MA50265A (fr) | Conjugués anticorps-récepteur alpha anti-folate et leurs utilisations | |
| MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
| MA43567A (fr) | Anticorps pacap et leurs utilisations | |
| MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
| MA45943A (fr) | Compositions ignifuges et leurs utilisations | |
| MA44262A (fr) | Bioconjugués et utilisations de ceux-ci | |
| MA43821A (fr) | Pyrimidines et variantes de celles-ci, et leurs utilisations | |
| MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
| MA41794A (fr) | Agents thérapeutiques modifiés et compositions associées |